Department of Radiotherapy, The First People's Hospital of Nantong, No. 6 Hai'er Xiang North Road, Nantong, P.R. China.
J Radiat Res. 2019 May 1;60(3):353-363. doi: 10.1093/jrr/rrz006.
The aim of this study was to observe dynamic changes in immunological parameters and levels of inflammatory factors from pre-radiotherapy to post-radiotherapy in patients with esophageal cancer, and to evaluate the related clinical prognosis. In all, 110 patients with esophageal cancer who underwent radiotherapy were enrolled. Before radiotherapy, post-radiotherapy, and 3 months after radiotherapy, the percentages of T lymphocyte subsets and natural killer (NK) cells in peripheral blood were detected using flow cytometry. The levels of serum inflammatory factors were measured with the enzyme-linked immunosorbent assay (ELISA). Thirty peripheral blood samples from healthy people were similarly analysed as the control. Before radiotherapy, the percentages of CD4+ and CD8+ T cells and NK cells, and the CD4+/CD8+ rate in esophageal cancer patients were significantly different from those in the healthy control group (P < 0.001); the levels of inflammatory factors were increased significantly (P < 0.001). The percentages of the above cells and the levels of inflammatory factors also differed statistically significantly between pre- and post-radiotherapy (P < 0.001) in the esophageal cancer patients. Three months after radiotherapy, the percentages of CD3+ (P = 0.453), CD4+ (P = 0.108), and CD8+ T cells (P = 0.163) and NK cells (P = 0.103) had recovered to the level before radiotherapy; and the levels of TNF-α (P = 0.101), IL-6 (P = 0.302) and IL-8 (P = 0.250) were also restored. After radiotherapy, alterations in immunological parameters were associated with the irradiation volume and the myelosuppression condition. Patients with recovered immunological parameters showed a longer median survival time than those with poor recovery of immunological parameters. For esophageal cancer patients who were immunosuppressive and had an activated inflammatory response before radiotherapy, radiotherapy aggravated these symptoms, and this aggravation was positively associated with myelosuppression and irradiation volume. In addition, recovery of the immunological parameters indicated better prognosis.
本研究旨在观察食管癌患者放疗前后免疫参数和炎症因子水平的动态变化,并评估其相关临床预后。共纳入 110 例接受放疗的食管癌患者。在放疗前、放疗后和放疗后 3 个月,采用流式细胞术检测外周血 T 淋巴细胞亚群和自然杀伤(NK)细胞的百分比。采用酶联免疫吸附试验(ELISA)检测血清炎症因子水平。同样分析了 30 例健康人外周血样本作为对照。放疗前,食管癌患者 CD4+和 CD8+T 细胞及 NK 细胞的百分比,以及 CD4+/CD8+比值均明显不同于健康对照组(P<0.001);炎症因子水平明显升高(P<0.001)。食管癌患者放疗前后上述细胞百分比和炎症因子水平也有统计学差异(P<0.001)。放疗后 3 个月,CD3+(P=0.453)、CD4+(P=0.108)、CD8+T 细胞(P=0.163)和 NK 细胞(P=0.103)的百分比恢复到放疗前水平;TNF-α(P=0.101)、IL-6(P=0.302)和 IL-8(P=0.250)的水平也恢复正常。放疗后免疫参数的改变与照射体积和骨髓抑制情况有关。免疫参数恢复良好的患者中位生存时间长于免疫参数恢复不良的患者。对于放疗前存在免疫抑制和炎症反应激活的食管癌患者,放疗加重了这些症状,这种加重与骨髓抑制和照射体积呈正相关。此外,免疫参数的恢复提示预后较好。